Related Experiment Videos
Glomerular expression of smooth-muscle myosin heavy-chain isoforms in aminonucleoside nephrosis in rats
T Nakamura1, K Kimura, I Ebihara
1Department of Medicine, Juntendo University School of Medicine, Tokyo, Japan.
Abstract:
1. We investigated the glomerular expression of three types of myosin heavy-chain isoforms, including S-myosin heavy-chain 40 (SM1), S-myosin heavy-chain 29 (SM2) and FS-myosin heavy-chain 34 (SMemb) in puromycin aminonucleoside nephrosis. 2. There was little change in SM1 and SM2 mRNA levels throughout the experiment. In contrast, glomerular SMemb mRNA increased on days 2 and 4 (before and soon after the onset of proteinuria, respectively), but declined on day 8 (the peak of proteinuria). 3. Histological myosin heavy-chain expression was examined using three antibodies against SM1, SM2 and SMemb. Immunohistochemically, SM1 and SM2 were absent in the glomeruli associated with puromycin aminonucleoside nephrosis until day 20. The SMemb isoform was barely detectable in normal glomeruli, but substantial amounts of SMemb were demonstrated in the glomeruli of rats with puromycin aminonucleoside nephrosis. In the puromycin aminonucleoside-treated rats, the number of SMemb-positive glomerular cells increased on days 2 and 4. 4. We examined whether levels of alpha-smooth-muscle actin or proliferating cell nuclear antigen correlated with myosin heavy-chain levels in the glomeruli of rats with puromycin aminonucleoside nephrosis. None of the cellular components in the glomeruli was positive for either alpha-smooth-muscle actin or proliferating cell nuclear antigen in puromycin aminonucleoside nephrosis. 5. Administration of methylprednisolone to puromycin aminonucleoside-treated rats resulted in the rapid disappearance of proteinuria. However, methylprednisolone did not affect SMemb mRNA or immunostaining in a glomeruli of rats with puromycin aminonucleoside nephrosis.(ABSTRACT TRUNCATED AT 250 WORDS)
Insights
FS-myosin heavy-chain 34 (SMemb) expression increased in glomeruli during puromycin aminonucleoside nephrosis, correlating with proteinuria onset. Steroid treatment reduced proteinuria but did not alter SMemb levels, suggesting it is a marker, not a therapeutic target.
Area of Science:
- Nephrology
- Molecular Biology
- Cell Biology
Background:
- Puromycin aminonucleoside (PAN) nephrosis is a model for studying glomerular injury and proteinuria.
- Myosin heavy-chain (MHC) isoforms play roles in cellular structure and function.
- Specific MHC isoform expression in glomerular cells during nephrotic injury is not well understood.
Purpose of the Study:
- To investigate the expression of SM1, SM2, and SMemb MHC isoforms in the glomeruli of rats with PAN nephrosis.
- To determine the correlation between SMemb expression and the development of proteinuria.
- To assess the effect of methylprednisolone treatment on SMemb expression in this model.
Main Methods:
- Quantitative analysis of SM1, SM2, and SMemb mRNA levels using RT-PCR.
- Immunohistochemical examination of SM1, SM2, and SMemb protein expression in glomeruli.
- Assessment of alpha-smooth-muscle actin and proliferating cell nuclear antigen as potential markers.
- Evaluation of proteinuria and the impact of methylprednisolone treatment.
Main Results:
- Glomerular SMemb mRNA and protein levels significantly increased during PAN nephrosis, particularly around the onset of proteinuria.
- SM1 and SM2 mRNA and protein levels showed minimal changes.
- No correlation was found between SMemb expression and alpha-smooth-muscle actin or proliferating cell nuclear antigen.
- Methylprednisolone treatment resolved proteinuria but did not affect SMemb expression.
Conclusions:
- FS-myosin heavy-chain 34 (SMemb) is upregulated in glomeruli during PAN-induced nephrosis, suggesting its role in the injury process.
- SMemb expression appears to be a marker of glomerular injury rather than a direct target for steroid therapy in this model.
- Further research is needed to elucidate the precise function of SMemb in glomerular pathology.